BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Fresenius SE & Co KGaA

Затворен

СекторЗдравеопазване

39.86 -0.2

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

39.7

Максимум

40.25

Ключови измерители

By Trading Economics

Приходи

-48M

271M

Продажби

264M

5.6B

P/E

Средно за сектора

24.381

57.333

Марж на печалбата

4.813

Служители

176,486

EBITDA

-33M

724M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+17.39% upside

Дивиденти

By Dow Jones

Следващи печалби

7.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.1B

22B

Предишно отваряне

40.06

Предишно затваряне

39.86

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Fresenius SE & Co KGaA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.02.2025 г., 13:37 ч. UTC

Пазарно говорене

European Stocks on Track for Record Close as Earnings Lift Mood -- Market Talk

5.06.2024 г., 12:18 ч. UTC

Пазарно говорене

Fresenius Helios Guidance Lift Should Drive Consensus Upgrades -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Fresenius SE & Co KGaA Прогноза

Ценова цел

By TipRanks

17.39% нагоре

12-месечна прогноза

Среден 46.78 EUR  17.39%

Висок 56.9 EUR

Нисък 42 EUR

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Fresenius SE & Co KGaA през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

11

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

39.5 / 39.92Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.